Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 402.24M P/E - EPS this Y - Ern Qtrly Grth -
Income -75.8M Forward P/E -3.33 EPS next Y -42.90% 50D Avg Chg 5.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -3.00%
Dividend N/A Price/Book 0.62 EPS next 5Y - 52W High Chg -41.00%
Recommedations 1.40 Quick Ratio 44.00 Shares Outstanding 245.69M 52W Low Chg 20.00%
Insider Own 24.53% ROA -9.65% Shares Float 135.84M Beta 1.37
Inst Own 55.07% ROE -12.03% Shares Shorted/Prior 3.01M/2.65M Price 1.83
Gross Margin - Profit Margin - Avg. Volume 508,546 Target Price 5.90
Oper. Margin - Earnings Date May 2 Volume 280,371 Change -3.17%
About Nuvation Bio Inc.

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

Nuvation Bio Inc. News
04/10/24 Nuvation Bio Completes Acquisition of AnHeart Therapeutics
03/28/24 Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer
03/25/24 Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction
03/14/24 Nuvation Bio Doses First Patient in Phase 1/2 Study of NUV-1511 for the Treatment of Advanced Solid Tumors
03/08/24 Nuvation Bio Inc. (NUVB) Is Up 25.28% in One Week: What You Should Know
02/29/24 Nuvation Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
02/27/24 12 Best Medical Stocks to Buy Under $10
02/17/24 Owning 46% shares,institutional owners seem interested in Nuvation Bio Inc. (NYSE:NUVB),
01/08/24 Nuvation Bio Announces Appointment of Dr. Robert Mashal to its Board of Directors
01/08/24 Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-1511 for the Treatment of Advanced Solid Tumors
12/04/23 Companies Like Nuvation Bio (NYSE:NUVB) Are In A Position To Invest In Growth
11/13/23 Nuvation Bio Announces Departure of Chief Financial Officer
11/02/23 Nuvation Bio Inc (NUVB) Reports Q3 2023 Financial Results
11/02/23 Nuvation Bio Reports Third Quarter 2023 Financial Results and Provides Business Update
10/23/23 One Nuvation Bio Insider Raised Their Stake In The Previous Year
08/03/23 Nuvation Bio Reports Second Quarter 2023 Financial Results and Provides Business Update
07/13/23 15 Best Penny Stocks To Buy Now
06/01/23 Nuvation Bio Announces Formation of Oncology-Focused Scientific Advisory Board
05/16/23 Nuvation Bio Insider Ups Holding During Year \
05/04/23 Nuvation Bio Reports First Quarter 2023 Financial Results and Provides Business Update
NUVB Chatroom

User Image BobBuran Posted - 2 hours ago

Friday This is the second of two posts showing a total of about 50 of my buy stop orders above the market for today. Already bot past ten minutes: $NUVB #stocks

User Image BobBuran Posted - 3 hours ago

Friday This is the first of two posts showing a total of about 50 of my buy stop orders above the market for today. Already bot past ten minutes: $NUVB #stocks

User Image echizzle Posted - 1 day ago

$NUVB huge bull flag when you zoom out on the chart

User Image Ruki_ Posted - 1 week ago

$NUVB I like that they immediately updated the pipeline on the website

User Image Ruki_ Posted - 1 week ago

$NUVB AnHeart is now a wholly-owned subsidiary of Nuvation Bio.

User Image Stock_Titan Posted - 1 week ago

$NUVB Nuvation Bio Completes Acquisition of AnHeart Therapeutics https://www.stocktitan.net/news/NUVB/nuvation-bio-completes-acquisition-of-an-heart-33ws3fj6w74v.html

User Image ZD7 Posted - 1 week ago

$NUVB entered @ 2.99

User Image algo888 Posted - 1 week ago

$STXS still up 3% and climbing!!! Bull Run above 3.30 on schedule!!! $DM $NUVB

User Image algo888 Posted - 2 weeks ago

$STXS breaking above 3.21 yesterday's HOD will trigger the algos!!! Get ready $BTBT $DM $NUVB

User Image algo888 Posted - 2 weeks ago

$STXS No selling pressure. make those traders watching on the sidelines chase it from 3.29 - 3.60 then from 4.00 - 5.00 LOL $DM $NUVB

User Image algo888 Posted - 2 weeks ago

$NUVB <<< made this pop from 1.50 to $4.15 my next explosive chart play: *** STXS **** https://www.tradingview.com/x/zAvpgRU5/

User Image analysis_first Posted - 2 weeks ago

$NUVB So NUVB trading at big negative enterprise value uses LESS THAN ZERO stock to pay positive $100mm for some company that itself would have been trading for a negative enterprise value if it were public, then the whole thing trades to +$500mm enterprise value? Give me a break.

User Image commoncentsinvestor Posted - 2 weeks ago

$NUVB ONE TO CHECK OUT FOR BIG GAINS IN 2024 Anyone looking for a stock that could have a big increase in share price in 2024 might want to take a look at CVRX. They got FDA approval for its Barostim product to improve the lives of people suffering from heart failure back in 2019. They have spent the last 4 years building a market for their product and it is about to reap big rewards. They have been increasing their revenues, the number of implant centers, their territories, , and their public visibility by leaps and bounds and work on 84% gross margins. This should all result in big increases in revenues and share price this year. I expect a minimum of $65M in 2024 revenues and with 84% Gross Margins, a 15 times Market Cap would be very reasonable. That would put the share price at about $47. Current Share Price is under $18. With only 600 followers on Stock Twits, it is very early in the game for folks who like to invest in under followed small companies with HUGE potential.

User Image ViractaTrader77 Posted - 2 weeks ago

Looks like Sutro can easily hit $7.50 per share. B of A must have sold some $5.18 shares to flippers when they are done I expect this to fly with the infusion of $165,000,000 yesterday between Ispen and the fundamental healthcare investors. $STRO $PYXS $VKTX $NUVB

User Image ViractaTrader77 Posted - 2 weeks ago

$STRO Similar ADC company to Sutro just got bought today for $1.8 billion. Lead drug targets folate receptor. https://www.biospace.com/article/genmab-leans-into-hot-adc-space-with-1-8b-profoundbio-acquisition-/ $NUVB

User Image Chrisgmya Posted - 2 weeks ago

$NUVB 💪💪💪

User Image JohnBoots Posted - 2 weeks ago

$STRO or $NUVB - which one would you pick?

User Image EreborExchange Posted - 2 weeks ago

$NUVB waiting

User Image EreborExchange Posted - 03/31/24

$NUVB on my radar!

User Image dixiebull Posted - 03/31/24

Happy Easter everyone! Might be SPAC/De-Spac time again, so we will be watching these ones about to combine....you can google a spac site, there are many $MESO pushed off 3.50 area for a move to break 5. See if 5 can hold for continuation to 5.50 and 6 $IBIO nice day trade/overnighter for us from 1.85 as it ran to test 5 res. See if 4 holds for a move to 5 $CERO made a nice run from 1.60s to 3.77, see if 3.25 holds for a move to 4 and 4.50, vwap 2.85 $NUVB holding around 3.50 support, with volume it can move to 4 and 4.50 $OUST beautiful move from 6.50 to 8.24, watch to see if 8 can break and hold for a move to 10

User Image Ruki_ Posted - 03/29/24

$NUVB Some good catalysts from this acquisition news. The party is just getting started. $IBB -Completion of Phase 2 studies for taletrectinib -Regulatory updates and potential approvals for taletrectinib, especially considering its Breakthrough Therapy Designations from the U.S. FDA and China’s NMPA. -Progress updates on safusidenib, particularly regarding its global Phase 2 study in patients with grades 2 and 3 IDH1-mutant glioma (NCT05303519). -Advancement of Nuvation Bio's internally discovered pipeline candidates, including Phase 1b studies of NUV-868 and the Phase 1/2 study of NUV-1511. -Integration efforts and synergies resulting from the acquisition of AnHeart, which could include updates on operational efficiencies and combined research and development initiatives.

User Image Chrisgmya Posted - 03/28/24

$NUVB

User Image ViractaTrader77 Posted - 03/28/24

Sutro has $300 million cash. Improved version of Immunogens drug that got approved acquired for $10 billion. Breaking out to billion dollar market cap. Plus they have a ror1 adc like the one Merck bought for billions. $NUVB $STRO

User Image BLtheKid Posted - 03/28/24

$NUVB it looks like Jeffries and now the silver-tongued devils at Wainright were successful in forcing buyers in at the high!

User Image algo888 Posted - 03/28/24

$NUVB dont miss the massive run-up on >>>>> B T B T

User Image _www_larval_com_ Posted - 03/28/24

$NUVB has sunk -6% lower to -2% (~2Mv) in the last few minutes, 04/19 options, follow for more volatility.

User Image Chrisgmya Posted - 03/28/24

$NUVB

User Image rtaker Posted - 03/28/24

$NUVB $NUVB MMs playing on retail patience and hitting stop losses this morning. There is no fear of dilution here and they know where the stock is headed.

User Image algo888 Posted - 03/28/24

$NUVB join me on my next explosive play similar to this >>>> **** BTBT

User Image erevnon Posted - 03/28/24

HC Wainwright & Co. maintains Nuvation Bio $NUVB at Buy and raises the price target from $5 to https://marketsblock.com/stock-upgrades-and-downgrades/

Analyst Ratings
RBC Capital Outperform Apr 17, 24
HC Wainwright & Co. Buy Mar 28, 24
Jefferies Buy Mar 27, 24
BTIG Buy Mar 26, 24
HC Wainwright & Co. Buy Mar 7, 24
Wedbush Outperform Mar 1, 24
HC Wainwright & Co. Buy Nov 22, 23
HC Wainwright & Co. Buy Aug 21, 23
RBC Capital Outperform May 5, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
NODELMAN OLEG Director Director Sep 19 Buy 1.33 5,313,100 7,066,423 12,674,775 09/22/23
NODELMAN OLEG Director Director Feb 19 Buy 1.33 5,313,100 7,066,423 12,674,775 09/21/23
Omega Fund V, L.P. 10% Owner 10% Owner Apr 05 Sell 5.60 2,500,000 14,000,000 20,457,340 04/07/22
Omega Fund V, L.P. 10% Owner 10% Owner Nov 22 Sell 9.76 295,036 2,879,551 24,857,376 11/24/21